@article{Han20181,

title = {Laparoscopic surgery for gallbladder cancer: An expert consensus statement},

author = {Ho-Seong Han and Yoo-Seok Yoon and Anil K. Agarwal and Giulio Belli and Osamu Itano and Andrew A. Gumbs and Dong Sup Yoon and Chang Moo Kang and Seung Eun Lee and Toshifumi Wakai and Roberto I. Troisi},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040715836&doi=10.1159%2f000486207&partnerID=40&md5=38683757b0f55e051a063ddca3d690ba},

doi = {10.1159/000486207},

issn = {02534886},

year  = {2018},

date = {2018-01-01},

urldate = {2018-01-01},

journal = {Digestive Surgery},

volume = {36},

number = {1},

pages = {1 – 6},

publisher = {S. Karger AG},

abstract = {Background: Despite the increasing number of reports on the favorable outcomes of laparoscopic surgery for gallbladder cancer (GBC), there is no consensus regarding this surgical procedure. Objective: The study aimed to develop a consensus statement on the application of laparoscopic surgery for GBC based on expert opinions. Methods: A consensus meeting among experts was held on September 10, 2016, in Seoul, Korea. Results: Early concerns regarding port site/peritoneal metastasis after laparoscopic surgery have been abated by improved preoperative recognition of GBC and careful manipulation to avoid bile spillage. There is no evidence that laparoscopic surgery is associated with decreased survival compared with open surgery in patients with early-stage GBC if definitive resection during/after laparoscopic cholecystectomy is performed. Although experience with laparoscopic extended cholecystectomy for GBC has been limited to a few experts, the postoperative and survival outcomes were similar between laparoscopic and open surgeries. Laparoscopic reoperation for postoperatively diagnosed GBC is technically challenging, but its feasibility has been demonstrated by a few experts. Conclusions: Laparoscopic surgery for GBC is still in the early phase of the adoption curve, and more evidence is required to assess this procedure. © 2018 S. Karger AG, Basel.},

note = {Cited by: 41; All Open Access, Bronze Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Aloia2015681,

title = {Gallbladder Cancer: Expert consensus statement},

author = {Thomas A. Aloia and Nicolas Járufe and Milind Javle and Shishir K. Maithel and Juan C. Roa and Volkan Adsay and Felipe J. F. Coimbra and William R. Jarnagin},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84936997973&doi=10.1111%2fhpb.12444&partnerID=40&md5=d2756a8412b3c2427ef787ac938f333d},

doi = {10.1111/hpb.12444},

issn = {1365182X},

year  = {2015},

date = {2015-01-01},

urldate = {2015-01-01},

journal = {HPB},

volume = {17},

number = {8},

pages = {681 – 690},

publisher = {Blackwell Publishing Ltd},

abstract = {An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists was convened on 15 January 2014 to review current evidence on the management of gallbladder carcinoma in order to establish practice guidelines. In summary, within high incidence areas, the assessment of routine gallbladder specimens should include the microscopic evaluation of a minimum of three sections and the cystic duct margin; specimens with dysplasia or proven cancer should be extensively sampled. Provided the patient is medically fit for surgery, data support the resection of all gallbladder polyps of >1.0 cm in diameter and those with imaging evidence of vascular stalks. The minimum staging evaluation of patients with suspected or proven gallbladder cancer includes contrasted cross-sectional imaging and diagnostic laparoscopy. Adequate lymphadenectomy includes assessment of any suspicious regional nodes, evaluation of the aortocaval nodal basin, and a goal recovery of at least six nodes. Patients with confirmed metastases to N2 nodal stations do not benefit from radical resection and should receive systemic and/or palliative treatments. Primary resection of patients with early T-stage (T1b-2) disease should include en bloc resection of adjacent liver parenchyma. Patients with T1b, T2 or T3 disease that is incidentally identified in a cholecystectomy specimen should undergo re-resection unless this is contraindicated by advanced disease or poor performance status. Re-resection should include complete portal lymphadenectomy and bile duct resection only when needed to achieve a negative margin (R0) resection. Patients with preoperatively staged T3 or T4 N1 disease should be considered for clinical trials of neoadjuvant chemotherapy. Following R0 resection of T2-4 disease in N1 gallbladder cancer, patients should be considered for adjuvant systemic chemotherapy and/or chemoradiotherapy. © 2015 International Hepato-Pancreato-Biliary Association.},

note = {Cited by: 233; All Open Access, Bronze Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}